A nitroimidazole-based hypoxic cell-radiation sensitizer and anti-infective against Trichomonas vaginalis.
Nimorazole is a nitroimidazole-based hypoxic cell-radiation sensitizer with less toxicity than etanidazole or misonidazole. Under low oxygen (hypoxic) condition, reductive activation of its 5-nitroimidazole moiety leads to enhanced adduct formation with reduced glutathione, which form the basis of cancer/tumour-selective radiation sensitization. Nimorazole is also a known anti-infective agent against trichomoniasis, an infectious disease caused by the protozoan parasite Trichomonas vaginalis.
Hypoxia is a characteristic feature of solid tumours that significantly reduces the efficacy of conventional radiation therapy. In this study we investigated the role of hypoxia in a stereotactic radiation schedule by using a variety of hypoxic modifiers in a
Tumour hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clinical outcomes. To find clinical candidate compounds that reduce hypoxia in tumours, we conduct a high-throughput screen for oxygen consumption rate (OCR) reduction and identify a number
Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole.
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
